Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Files An 8-K Results of Operations and Financial ConditionItem 2.02
On August8, 2017, Agios Pharmaceuticals, Inc. (the “Company”) issued a press release announcing its results for the quarter ended June30, 2017 and other business highlights. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form8-K.
The information in this Form 8-K, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.
| Item 2.02 | Financial Statements and Exhibits. |
(d) Exhibits.
|
Exhibit No. |
Description |
| 99.1 | Press release issued August8, 2017. |
AGIOS PHARMACEUTICALS INC ExhibitEX-99.1 2 d438574dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Agios Reports Second Quarter 2017 Financial Results – IDHIFA® (enasidenib) Granted Approval from FDA as First Targeted Therapy for Patients with IDH2m R/R AML and First Product Approved from Agios’ Discovery Platform – – Trial Designs Finalized for Two Pivotal Studies for AG-348 in Pyruvate Kinase Deficiency; Studies on Track to Begin in 1H2018 – – Initiated Ivosidenib Phase 3 Study (AGILE) in Newly Diagnosed IDH1m AML; NDA Submission for R/R AML on Track for Year End 2017 – CAMBRIDGE,…To view the full exhibit click here
About Agios Pharmaceuticals, Inc. (NASDAQ:AGIO)
Agios Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is engaged in the discovery and development of orally available small molecule medicines for the treatment of cancer and rare genetic disorders (RGDs), which are a subset of orphan genetic metabolic diseases. Its cancer product candidates are AG-221 and AG-120, which targets mutated isocitrate dehydrogenase 2 and 1, or IDH2 and IDH1, respectively, and AG-881, which targets both mutated IDH1 and mutated IDH2. The lead product candidate in its RGD programs, AG-348, targets pyruvate kinase-R for the treatment of pyruvate kinase deficiency. Its AG-221 is an orally available, selective, inhibitor of the mutated IDH2 protein indicated for the treatment of patients with cancers. Its AG-120 is an orally available, selective, inhibitor of the mutated isocitrate dehydrogenase (IDH1) protein for the treatment of patients with cancers. AG-881 is an orally available, selective, brain-penetrant, pan-IDH mutant inhibitor.
